Titel: Förändrad livsstil kan förhindra typ 2-diabetes. Interventionsstudier visar goda resultat hos "prediabetiker" [summary] 2007 nr 49 sid 3771-4

Läs/ladda hem artikeln: Översikt Fullständig referenslista Artikeln i pdf-format (utskriftskvalitet) Sid 3771 Sid 3772 Sid 3773 Sid 3774 Om Läkartidningens fulltext på Internet Hämta Acrobat Reader

Ämnesord:
Livsstil
Typ 2-diabetes
Primärprevention
Evidensbaserad medicin
















Sök liknande artiklar (ny funktion på försök)

Summary:
Type 2 diabetes mellitus is a serious progressive disease where life expectancy is shortened. Therefore it is important to prevent or to delay the development of the disease. In recent years, several good clinical trials, both using lifestyle- or pharmacological interventions, in individuals at high risk i. e. with intermediate hyperglycemia, have reported favourable results. These studies have shown that it is possible to reduce the incidence of diabetes. We therefore recommend, as first choice, lifestyle interventions because they are effective, safe and promote good health.

Stefan Jansson, Peter Engfeldt

Correspondence: Stefan Jansson, Institutionen för klinisk medicin/Allmänmedicinskt forskningscentrum, Örebro universitet, Box 1613, SE-701 16 Örebro, Sweden stefan.jansson@orebroll.se

Referenser:
1.World Health Organization. The prevention of diabetes and its complications [homepage on the Internet]. Geneva: WHO; 2006 [cited 2007 June 7]. Available from: http://www.who.int/diabetes/preventionflyer/en/.
2.Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. Bmj 2007;334(7588):299.
3.Berger B. Epidemiology of diabetes in a well defined population in Sweden : the Skaraborg Diabetes Registry [dissertation ]. Malmö: Lund University; 2006.
4.Davies MJ, Tringham JR, Troughton J, Khunti KK. Prevention of Type 2 diabetes mellitus. A review of the evidence and its application in a UK setting. Diabet Med 2004;21(5):403-14.
5.Andersson DK, Svärdsudd K. Long-term glycemic control relates to mortality in type II diabetes. Diabetes Care 1995;18(12):1534-43.
6.Jansson SP, Andersson DK, Svärdsudd K. Prevalence and incidence rate of diabetes mellitus in a Swedish community during 30 years of follow-up. Diabetologia 2007;50(4):703-10.
7.Rose G. Sick individuals and sick populations. Int J Epidemiol 2001;30(3):427-32; discussion 33-4.
8.Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002;19(9):708-23.
9.Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20(4):537-44.
10.Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344(18):1343-50.
11.Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393-403.
12.Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract 2005;67(2):152-62.
13.Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006;49(2):289-97.
14.Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002;51(9):2796-803.
15.Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005;54(4):1150-6.
16.Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359(9323):2072-7.
17.Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27(1):155-61.
18.Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368(9541):1096-105.
19.Melander A, Lindblad U, Lindberg G, Tyrberg M. Can sulphonylurea addition to life-style changes help to delay diabetes development in subjects with impaired fasting glucose (IFG)? - the NANSY STUDY [abstract]. Diabetes Vasc Dis Res 2007;4(Suppl 1):S24.
20.Eriksson KF, Lindgärde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia 1991;34(12):891-8.
21.Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. Jama 2003;290(4):486-94.
22.Henriksson F, Agardh CD, Berne C, Bolinder J, Lönnqvist F, Stenström P, et al. Direct medical costs for patients with type 2 diabetes in Sweden. J Intern Med 2000;248(5):387-96.
23.Koopmanschap M. Coping with Type II diabetes: the patient's perspective. Diabetologia 2002;45(7):S18-22.
24.Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005;142(5):323-32.
25.Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemiö K, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006;368(9548):1673-9.
26.Andersson DK, Petersson C. [Screening for type 2 diabetes is justified]. Läkartidningen 1998;95(46):5167-70, 75.
27.Yates T, Khunti K, Bull F, Gorely T, Davies MJ. The role of physical activity in the management of impaired glucose tolerance: a systematic review. Diabetologia 2007;50(6):1116-26.
28.Nathan DM, Davidson MB, Defronzo RA, Heine RJ, Henry RR, Pratley R, et al. Impaired Fasting Glucose and Impaired Glucose Tolerance: Implications for care. Diabetes Care 2007;30(3):753-9.
29.Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366(9493):1279-89.
30.Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355(23):2427-43.
31.Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. N Engl J Med 2007.
32.Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, et al. Rosiglitazone Evaluated for Cardiovascular Outcomes -- An Interim Analysis. N Engl J Med 2007.